Welcome!

News Feed Item

2019 Forecasts: Pancreatic Adenocarcinoma & HIV Therapeutics in Major Developed Markets

DALLAS, April 26, 2014 /PRNewswire/ --


RnRMarketResearch.com offers Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant and HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth research reports in its store.

Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9% due to patent expirations of several key therapies says the report HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth available at http://www.rnrmarketresearch.com/hiv-therapeutics-in-major-developed-markets-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth-market-report.html .

The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. These include the impact of the drugs approved in the forecast period, but also the increase in the prevalence of the disease and minor improvements in diagnostics that result in more patients being eligible for pharmacological as per the report Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant available at http://www.rnrmarketresearch.com/pancreatic-adenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant-market-report.html .

As per HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth report, the first-line antiretroviral therapies Atripla and Truvada will lose patent protection during the forecast period, which will hurt their markets in Europe and Canada. Analyst of this report says: "Despite such patent losses, a number of drugs will enter the HIV market by 2019. Among these new entrants, 572-Trii is expected to perform the strongest commercially and will compete with Atripla following its approval. However, these drugs will not offset the impact of generic erosion."

Currently, the HIV pipeline is strong and displays a high degree of novelty and diversity, according to this research. The pipeline also consists of therapies that address the unmet needs of drug resistance and toxicity. These drugs are Nucleoside Reverse Transcriptase Inhibitor (NRTI) apricitabine, censavudine and elvucitabine, which deal with the issue of NRTI resistance.

Another candidate in the HIV pipeline, which is a new pro-drug of tenofovir, called tenofovir alafenamide, has also demonstrated a more favorable toxicity profile than its predecessor Viread.

The analyst further says: "Despite the promising outlook, the HIV pipeline has suffered from high attrition rates in recent years, particularly with vaccines. None of these have been approved for the treatment of HIV. These failures reflect an urgent need for a more thorough understanding of immune response against HIV and more streamlined clinical trial designs". Order a copy of the HIV therapeutics market at http://www.rnrmarketresearch.com/contacts/purchase?rname=168415 .

Products discussed in the Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant report include Gemcitabine, IV Fluorouracil, Tarceva, Abraxane, Teysuno/TS-1, Xeloda and Eloxatin. The promising drug candidates in pipeline discussed in this research are Masivet/Kinavet (US) - AB Science, Glufosfamide - Eleison Pharmaceuticals Incorporated¸ Tertomotide - Kael-GemVax Co., Ltd¸ TH-302 - Threshold Pharmaceuticals¸ HyperAcute Pancreas - NewLink Genetics Corporation and MM-398 - Merrimack Pharmaceuticals Inc. Following industry licensing and co-development deals have been discussed in this report:

  • Clavis Enters Licensing and Development Agreement with Clovis
  • Baxter Enters Licensing Agreement with Onconova for Rigosertib
  • Lorus Therapeutics Enters Into Licensing Agreement with Zor Pharma
  • Novogen Enters Into Licensing Agreement with Marshall Edwards For NV-196 And NV-143
  • Merck Serono Enters Into Co-Development Agreement with Threshold Pharma for TH-302

Pancreatic Adenocarcinoma Therapeutics Market forecasts to 2019 have been provided for global region as well as US, Canada, UK, France, Germany, Italy, Spain and Japan. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=168412 .

Explore more reports on the therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics  and on the pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com (http://www.rnrmarketresearch.com/ ) is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact: 

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

http://www.lifescienceindustryresearch.com/latest-reports

Connect With Us on: 

Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Twitter: https://twitter.com/RnRMR

G+: https://plus.google.com/u/0/104156468549256253075/

RSS: http://www.rnrmarketresearch.com/feed


SOURCE RnRMarketResearch.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
"Peak 10 is a hybrid infrastructure provider across the nation. We are in the thick of things when it comes to hybrid IT," explained Michael Fuhrman, Chief Technology Officer at Peak 10, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Calligo, an innovative cloud service provider offering mid-sized companies the highest levels of data privacy and security, has been named "Bronze Sponsor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Calligo offers unparalleled application performance guarantees, commercial flexibility and a personalised support service from its globally located cloud plat...